OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Haematology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Zanubrutinib-associated ecchymotic lesions	425
Correction to Lancet Haematol 2023; 10: e333–45	346
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	219
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	191
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	182
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	166
Towards reparatory measures: blood donation, health systems, and men who have sex with men	150
Correction to Lancet Haematol 2024; 11: e114–26	145
In the trenches	135
Prioritising health equity alongside donation safety – Authors' reply	129
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	127
MRD-guided treatment cessation in multiple myeloma	125
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	118
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	106
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	105
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	99
Blood cell defence against pathogens	99
Rituximab versus active surveillance in patients with follicular lymphoma	98
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	90
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	90
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	82
Extensively distributed erythema nodosum in VEXAS syndrome	81
Correction to Lancet Haematol 2025; 12: e294–303	77
Production and supply of blood products in Brazil	76
Correction to Lancet Haematol 2023; 10: e433–44	75

International Society on Thrombosis and Haemostasis Congress 2023	75
Be compliant or compromise?	74
Bedside art is good medicine	74
Blood deserts: a vision to tackle blood inaccessibility	70
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	69
Artwork from trauma: the social life of medical data	67
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	67
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	66
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	66
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	65
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	65
Sickle cell disease in India: current status and progress	64
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	63
Anaemia in a time of climate crisis	59
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	59
USAID's enduring impact on anaemia management must be preserved	59
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	58
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	58
Coexisting genetic abnormalities and thrombocytopenia	58
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	57
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	56
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	54
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	54
Correction to Lancet Haematol 2024; 11: e310–11	53
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	53
Oreofe Odejide—aiming to raise the bar in haematology care	52
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	51
Correction to Lancet Haematol 2022; 9: e200–07	51